What is B. Riley's Forecast for TG Therapeutics Q4 Earnings?

Key Points

• B. Riley has revised TG Therapeutics' Q4 2025 earnings per share (EPS) estimate down to $0.33, lowering it from a previous forecast of $0.36, while still maintaining a "Buy" rating with a price target of $55.00.
• Goldman Sachs upgraded TG Therapeutics to a "Hold" rating and set a target price of $37.00, positioning the stock as a Moderate Buy with an average target of $48.00 from analysts.
• In recent trading, TG Therapeutics shares are priced at $32.61, having a market capitalization of $5.17 billion and a PE ratio of 88.14.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Investment analysts at B. Riley cut their Q4 2025 earnings per share estimates for TG Therapeutics in a research note issued on Wednesday, September 17th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn $0.33 per share for the quarter, down from their prior estimate of $0.36. B. Riley has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' FY2026 earnings at $1.74 EPS and FY2029 earnings at $4.44 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The company had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business's revenue was up 92.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS.

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research note on Thursday, July 10th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $48.00.

TG Therapeutics Stock Performance

Shares of TGTX stock traded up $0.62 during trading hours on Friday, reaching $35.59. 706,113 shares of the company traded hands, compared to its average volume of 2,452,933. TG Therapeutics has a 12-month low of $21.16 and a 12-month high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The company has a market cap of $5.65 billion, a P/E ratio of 96.23 and a beta of 1.88. The firm has a 50-day moving average price of $31.84 and a 200 day moving average price of $35.63.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.64% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently bought and sold shares of TGTX. Johnson Financial Group Inc. acquired a new stake in shares of TG Therapeutics in the second quarter valued at approximately $25,000. Ameritas Advisory Services LLC purchased a new stake in shares of TG Therapeutics in the second quarter valued at about $25,000. NBC Securities Inc. grew its holdings in shares of TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the period. Golden State Wealth Management LLC grew its holdings in shares of TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the period. Finally, SVB Wealth LLC purchased a new stake in shares of TG Therapeutics in the first quarter valued at about $37,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.